CytoSPAR specializes in using the power of advanced science to transform disease management with simplified diagnostic solutions. A flagship technology, blAST, uses direct sample phenotypic antimicrobial susceptibility testing (AST) to accelerate the process of identifying effective antimicrobial agents while reducing the time-to-results from days to mere hours.  This rapid turnaround is crucial in the fight against antimicrobial resistance (AMR), ensuring patients a more timely and effective treatment. 

Visit our website to learn how CytoSPAR is developing solutions to diagnostic dilemmas.

CytoSPAR

Org chart

Teams

Offices